viewAllergy Therapeutics PLC

Allergy Therapeutics gets big forecast upgrade from finncap after trading update

The broker now expects profits to around £5m higher than its previous forecasts at £2.9m.

Allergy Therapeutics PLC -

Allergy Therapeutics PLC (LON:AGY) has had forecasts for the current year sharply upgraded by broker finnCap after a bullish trading update today.

The broker now expects profits to around £5m higher than its previous forecasts at £2.9m.

“Given the balance sheet (c.£29m net cash at 30 June 2020), underlying growth and previous clinical trial successes, we believe the risk/reward profile is highly attractive and reiterate our target price of 40p,” it said.

Earlier, the allergy vaccines specialist had said revenues for the 12 months ended June 30 would be at least 4% ahead of the comparable period last year on a constant currency basis.

The swing factors were operating cost efficiencies and the timing of the planned research and development expenditure.

A further update is planned for the week beginning July 13.

Quick facts: Allergy Therapeutics PLC

Price: 14 GBX

Market: AIM
Market Cap: £89.22 m


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Allergy Therapeutics PLC named herein, including the promotion by the Company of Allergy Therapeutics PLC in any Content on the Site, the...



Market Report: Coronavirus vaccine update sparks FTSE 100 rally

Headlines from the Proactive UK newsroom. The FTSE 100 rallied 60 points to 6,240 on COVID-19 vaccine hopes. US group Moderna’s early stage trial of a coronavirus vaccine proved safe and sparked some immune response. UK inflation picked up to 0.6% led by demand for online computer games...

4 weeks ago

2 min read